Sjögren's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, February 2012, Pages: 59

Sjögren’s Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Sjögren’s Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Sjogren's Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Sjogren's Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Sjogren's Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Sjogren's Syndrome Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Sjogren's Syndrome Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Sjogren's Syndrome Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Sjogren's Syndrome Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Sjogren's Syndrome Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Sjogren's Syndrome Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Sjogren's Syndrome Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Sjogren's Syndrome Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Sjögren’s Syndrome Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Signs and Symptoms
2.3.1 Ocular Manifestation:
2.3.2 Oral Manifestation:
2.3.3 Systemic Manifestation:
2.4 Etiology
2.5 Pathophysiology
2.5.1 Cell Mediated
2.5.2 Inflammatory response
2.6 Diagnosis of Sjögren’s Syndrome
2.7 Treatment and Management Pattern:
2.8 GlobalData Pipeline Report Guidance
3 Sjögren’s Syndrome Therapeutics - Market Characterization
3.1 Overview
3.2 Sjögren’s Syndrome Therapeutics Market Size (2006-2011) - Global
3.3 Sjögren’s Syndrome Therapeutics Market Forecast (2011-2019) - Global
3.4 Sjögren’s Syndrome Therapeutics Market Size (2006-2011) - The US
3.5 Sjögren’s Syndrome Therapeutics Market Forecast (2011-2019) - The US
3.6 Sjögren’s Syndrome Therapeutics Market Size (2006-2011) - France
3.7 Sjögren’s Syndrome Therapeutics Market Forecast (2011-2019) - France
3.8 Sjögren’s Syndrome Therapeutics Market Size (2006-2011) - Germany
3.9 Sjögren’s Syndrome Therapeutics Market Forecast (2011-2019) - Germany
3.10 Sjögren’s Syndrome Therapeutics Market Size (2006-2011) - Italy
3.11 Sjögren’s Syndrome Therapeutics Market Forecast (2011-2019) - Italy
3.12 Sjögren’s Syndrome Therapeutics Market Size (2006-2011) - Spain
3.13 Sjögren’s Syndrome Therapeutics Market Forecast (2011-2019) - Spain
3.14 Sjögren’s Syndrome Therapeutics Market Size (2006-2011) - The UK
3.15 Sjögren’s Syndrome Therapeutics Market Forecast (2011-2019) - The UK
3.16 Sjögren’s Syndrome Therapeutics Market Size (2006-2011) - Japan
3.17 Sjögren’s Syndrome Therapeutics Market Forecast (2011-2019) - Japan
3.18 Drivers and Barriers for the Sjögren’s Syndrome Therapeutics Market
3.18.1 Drivers for the Sjögren’s Syndrome Therapeutics Market
3.18.2 Barriers for the Sjögren’s Syndrome Therapeutics Market
3.19 Key Events Impacting the Future Market
3.20 Opportunity and Unmet Need
3.21 Key Takeaway
4 Sjögren’s Syndrome Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Portfolio for Major Marketed Products in the Sjögren’s Syndrome Therapeutics Market
4.3.1 Stimulants
4.3.2 Disease Modifying Drugs (DMARDS)
4.3.3 Corticosteroids
4.3.4 Off- Label and Over the Counter Drugs
4.4 Key Takeaway
5 Sjögren’s Syndrome Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Sjögren’s Syndrome Pipeline - Pipeline by Phases of Development
5.3.1 Sjögren’s Syndrome Therapeutics - Phase III Pipeline
5.3.2 Sjögren’s Syndrome Therapeutics - Phase II Pipeline
5.3.3 Sjögren’s Syndrome Therapeutics - Phase I Pipeline
5.4 Sjögren’s Syndrome Pipeline by Mechanism of Action
5.5 Sjögren’s Syndrome Technology Trends Analytical Framework
5.6 Sjögren’s Syndrome Therapeutics - Promising Drugs under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 P-552-02
5.8 Key Takeaway
6 Sjögren’s Syndrome Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Sjögren’s Syndrome Therapeutics Clinical Trials
7 Sjögren’s Syndrome Therapeutics - Strategic Assessment
7.1 Future Market Competition Scenario
8 Sjögren’s Syndrome Therapeutics - Future Players
8.1 Introduction
8.2 Parion Sciences
8.3 Kainos Medicine, Inc.
9 Sjögren’s Syndrome Therapeutics - Licensing and Partnership Deals
10 Sjögren’s Syndrome Therapeutics - Appendix
10.1 Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: American-European Revised Consensus Criteria for Sjögren’s Syndrome
Table 2: Sjögren’s Syndrome Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Table 3: Sjögren’s Syndrome Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Table 4: Sjögren’s Syndrome Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 5: Sjögren’s Syndrome Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 6: Sjögren’s Syndrome Therapeutics Market, France, Revenue ($m), 2006-2011
Table 7: Sjögren’s Syndrome Therapeutics Market, France, Forecast ($m), 2011-2019
Table 8: Sjögren’s Syndrome Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 9: Sjögren’s Syndrome Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 10: Sjögren’s Syndrome Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 11: Sjögren’s Syndrome Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 12: Sjögren’s Syndrome Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 13: Sjögren’s Syndrome Therapeutics Market, Spain, Forecasts ($m), 2011-2019
Table 14: Sjögren’s Syndrome Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 15: Sjögren’s Syndrome Therapeutics Market, the UK, Forecasts ($m), 2011-2019
Table 16: Sjögren’s Syndrome Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 17: Sjögren’s Syndrome Therapeutics Market, Japan, Forecasts ($m), 2011-2019
Table 18: Salagen Clinical Study Details
Table 19: Evoxac Clinical Study Details
Table 20: Sjögren’s Syndrome Therapeutics - Phase III Pipeline, 2011
Table 21: Sjögren’s Syndrome Therapeutics - Phase II Pipeline, 2011
Table 22: Sjögren’s Syndrome Therapeutics - Phase I Pipeline, 2011
Table 23: Sjögren’s Syndrome Therapeutics - Promising Drugs Under Clinical Development, 2011
Table 24: Sjögren’s Syndrome Therapeutics - Clinical Trials by Country, 2011
Table 25: Sjögren’s Syndrome Therapeutics - Clinical Trials by Phase, 2011
Table 26: Sjögren’s Syndrome Therapeutics - Clinical Trials by Status, 2011
Table 27: Sjögren’s Syndrome Therapeutics - Overall Sponsors, 2011
Table 28: Sjögren’s Syndrome Therapeutics - Prominent Sponsors, 2011
Table 29: Sjögren’s Syndrome Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 30: Parion Sciences - Sjögren’s Syndrome Therapeutics Pipeline, November 2011
Table 31: Parion Sciences - Sjögren’s Syndrome Therapeutics Pipeline, November 2011
Table 32: Kainos Medicine, Inc. - Sjögren’s Syndrome Therapeutics Pipeline, November 2011
Table 33: Kainos Medicine, Inc.- Sjögren’s Syndrome Therapeutics Pipeline, November 2011

1.2 List of Figures
Figure 1: Secretory Function in Unaffected People
Figure 2: Algorithm for the Treatment and Management of Sjögren’s Syndrome
Figure 3: Sjögren’s Syndrome Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Figure 4: Sjögren’s Syndrome Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Figure 5: Sjögren’s Syndrome Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 6: Sjögren’s Syndrome Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 7: Sjögren’s Syndrome Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 8: Sjögren’s Syndrome Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 9: Sjögren’s Syndrome Therapeutics Market, Germany , Revenue ($m), 2006-2011
Figure 10: Sjögren’s Syndrome Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 11: Sjögren’s Syndrome Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 12: Sjögren’s Syndrome Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 13: Sjögren’s Syndrome Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 14: Sjögren’s Syndrome Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 15: Sjögren’s Syndrome Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 16: Sjögren’s Syndrome Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 17: Sjögren’s Syndrome Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 18: Sjögren’s Syndrome Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 19: Sjögren’s Syndrome Therapeutics, Key Events Impacting Future Market, 2011
Figure 20: Opportunity and Unmet Need in the Sjögren’s Syndrome Therapeutics Market, 2011
Figure 21: Strategic Competitor Assessment of the Major Marketed Products for Sjögren’s Syndrome, 2011
Figure 22: Sjögren’s Syndrome Therapeutics Pipeline by Phase of Development, 2011
Figure 23: Sjögren’s Syndrome - Clinical Pipeline by Mechanism Of Action, 2011
Figure 24: Technology Trends Analytical Framework, 2011
Figure 25: Technology Trends Analytical Framework - Description, 2011
Figure 26:Clinical Trial Details for P-552-02
Figure 27: Sjögren’s Syndrome Therapeutics - Clinical Trials by Country, 2011
Figure 28: Sjögren’s Syndrome Therapeutics - Clinical Trials by Phase, 2011
Figure 29: Sjögren’s Syndrome Therapeutics - Clinical Trials by Status, 2011
Figure 30: Sjögren’s Syndrome Therapeutics - Overall Sponsors, 2011
Figure 31: Sjögren’s Syndrome Therapeutics - Prominent Sponsors, 2011
Figure 32: Sjögren’s Syndrome Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 33: Sjögren’s Syndrome Therapeutics, Strategic Assessment, 2011
Figure 34: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Sjögren’s Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Sjögren’s syndrome therapeutics market and identifies the key trends shaping and driving it. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Sjögren’s syndrome therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Sjögren’s Syndrome Therapeutics Market is Forecast to Show Steady Growth until 2019

GlobalData estimates the global Sjögren’s syndrome therapeutics market to be worth $411m in 2011. It is expected to grow to $626m at a Compound Annual Growth Rate (CAGR) of 5.4% by 2019. The growth in the market is primarily attributed to the increasing prevalence and an increase in the rate of diagnosis. The market is currently underserved as the available treatment options provide only symptomatic relief. Moreover, there is no single therapy approved for both primary and secondary Sjögren’s syndrome. Evoxac (cevimeline) is approved in the US for xerostomia (dry mouth) associated with Sjögren’s syndrome. Pilocarpine is a generic, approved for xerostomia associated with Sjögren’s syndrome. However, physicians prefer to prescribe Salagen, a brand for pilocarpine. The current market demands new drugs with novel mechanisms of action to potentially treat and cure the disease in totality.

Current Treatment Options Leave High Level of Unmet Need

The current competition in the Sjögren’s syndrome therapeutics market is weak. There is significant opportunity for new entrants that are able to offer a disease-targeting approach. Only two drugs (pilocarpine (brand name Salagen) and cevimeline marketed as Evoxac) are approved for symptomatic relief. Other treatment options include generics, over the counter medication and off-label drugs with low safety profiles. The current therapies only offer symptomatic treatment for Sjögren’s syndrome. New drugs able to reduce the severity or provide a disease-targeting mechanism will be able to successfully capture the Sjögren’s syndrome therapeutics market.

Parion Sciences
Kainos Medicine, Inc

Customers who bought this item also bought

• Connective Tissue Diseases: Atlas of Investigation and Management
• Irritable Bowel Syndrome (IBS) Therapeutics - Global Strategic Business Report
• Medical Nutrition - A Global Market Overview
• Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets
• Oral Medicine - A Color Handbook, 2nd Edition
• Diabetes Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Orphan Disease Series - Glaucoma: Can Orphan-Drug Status Offer an Entry into a Mature Market?
• Molecular Diagnostics - Global Strategic Business Report